Radiomics-driven spectral profiling of six kidney stone types with monoenergetic CT reconstructions in photon-counting CT.

Objectives: Urolithiasis, a common and painful urological condition, is influenced by factors such as lifestyle, genetics, and medication. Differentiating between different types of kidney stones is crucial for personalized therapy. The purpose of this study is to investigate the use of photon-counting computed tomography (PCCT) in combination with radiomics and machine learning to develop a method for automated and detailed characterization of kidney stones.

Automated Kidney Stone Composition Analysis with Photon-Counting Detector CT, a Performance Study-A Phantom Study.

Background: For treatment of urolithiasis, the stone composition is of particular interest, as uric acid (UA) stones can be treated by chemolitholysis. In this ex vivo study, we employed an advanced composition analysis approach for urolithiasis utilizing spectral data obtained from a photon-counting detector CT (PCDCT) to differentiate UA and non-UA stones. Our primary objective was to assess the accuracy of this analysis method.

Abemaciclib and Letrozole in Metastatic Male Breast Cancer.

Background: Male breast cancer is a very rare disease and only accounts for around 1% of all breast cancers. The treatment strategies are based on those used for breast cancer in women. So far, there is a lack of randomized data to support specific treatment modalities in men.

Radiological Assessment of Different Retroperitoneal Lymph Node Measurements in Stage 1 Testicular Cancer Patients: Impact on Clinical Stage and Treatment.

In staging for testicular germ cell tumor (GCT), current guidelines lack consensus regarding the measurement of retroperitoneal lymph node metastasis, concerning the recommended plane and dimension. This exploratory study aimed to assess its impact on clinical stage (cS) and therapy. We retrospectively examined 154 cSI (retroperitoneal lymph nodes < 10 mm in axial short-axis diameter (SAD)) GCT patients, without adjuvant therapy and a follow-up ≥ 24 months.